Search
Results : 3 ( "Tumor necrosis factor inhibitors"[Keywords] ) AND "2023 ~ 2024"[Year]
-
Original ArticleOctober 1, 2024
0
1047
251
Anemia as an indicator of a higher retention rate for tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis from a Korean multi-center registry
Jung Gon Kim
J Rheum Dis 2024; 31(4): 212-222
, M.D., M.S., Bon San Koo , M.D., Ph.D., Joo-Hyun Lee , M.D., Ph.D., Bo Young Yoon , M.D., Ph.D. -
Original ArticleApril 1, 2024
0
1240
533
Real-world effectiveness of a single conventional disease-modifying anti-rheumatic drug (cDMARD) plus an anti-TNF agent versus multiple cDMARDs in rheumatoid arthritis: a prospective observational study
Min Wook So
J Rheum Dis 2024; 31(2): 86-96, M.D., Ph.D., Sang-Hyon Kim , M.D., Ph.D., Dong Wook Kim , M.D., Ph.D., Yoon-Kyoung Sung , M.D., Ph.D., MPH, Jung-Yoon Choe , M.D., Ph.D., Sang-Il Lee , M.D., Ph.D., Jin-Wuk Hur , M.D., Ph.D., Hye-Soon Lee , M.D., Ph.D., Sang-Heon Lee , M.D., Ph.D., Jin Ran Kim , PharmD -
Original ArticleJanuary 1, 2024
Impact of anti-tumor necrosis factor treatment on lipid profiles in Korean patients with ankylosing spondylitis
Inbeom Kwon
J Rheum Dis 2024; 31(1): 41-48, M.D., Nayeon Choi , M.S., Ji Hui Shin , M.S., Seunghun Lee , M.D., Ph.D., Bora Nam , M.D.,Ph.D., Tae-Hwan Kim , M.D., Ph.D.
Full Text
Cite
Share- 1
Oct 01, 2024
Vol.31 No.4, pp. 191~263
COVER PICTURE
Ancestry-driven pathways for SLE-risk SNP-associated genes. The ancestry-driven key signaling pathways in Asians, Europeans, and African Americans were analyzed by enrichr (https://maayanlab.cloud/Enrichr/#libraries) using non-HLA SNP-associated genes. SLE: systemic lupus
erythematosus, SNP: single-nucleotide polymorphism, JAK–STAT: janus kinase–signal transducers and activators of transcription, IFN: interferon gamma. (J Rheum Dis 2024;31:200-211)
